Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO-1.01 versus gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
NL-OMON36550Phase 2Active, not recruiting
- Sponsor
- Clovis Oncology
- Start
- Nov 2011
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing CO-1.01 with gemcitabine (2 arms). Primary endpoint: Overall survival in patients with low hENT1 expression. Started Nov 2011; status: active, not recruiting.
02
Drugs
gemcitabine elaidategemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON36550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36550.